We factor revenue/PAT CAGR of 13%/14.7% over FY18-20E driven by uptick in rural demand, new product launches and market share gains. We upgrade the stock to BUY as Dabur with its wide product portfolio and distribution reach is well placed to capitalize on recovery in rural demand. We...